Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery: a Randomized, Double-blind Trial

NCT07859176 is registered in ClinicalTrials.gov with General Committee of Teaching Hospitals and Institutes, Egypt as lead sponsor.

NCT NCT07859176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07859176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery: a Randomized, Double-blind Trial
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

morbid obesity